{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    51,
    58,
    59
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_v7",
        "affectedSection": "Section 7 - Statistical Methods & Determination of Sample Size",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Sample size increased to approximately 240 subjects to accommodate more countries and higher dropout rates."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_v7",
        "affectedSection": "Section 5.1 - Eligibility Criteria",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Modified eligibility criteria to exclude subjects positive for COVID-19."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_v7",
        "affectedSection": "Section 4.3 - Loading Dose, Continuous Infusion Rates, Titration, and Extra Doses",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Clarified flexibility in F3 infusion rate reduction beyond the standard 20% limit."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_v7",
        "affectedSection": "Section 5.8 - Study Drug and Study Devices",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Added guidance on cannula length selection and infusion site rotation."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_v7",
        "affectedSection": "Section 6.1 - Complaints and Adverse Events",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Updated reporting timeframe for product complaints to 24 hours."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_v7",
        "reasonText": "Necessary protocol modifications due to the COVID-19 pandemic to minimize subject risk.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_v7",
        "reasonText": "To mitigate the risk of muscle wall infiltration leading to pain and/or occlusion of the cannula.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_v7",
        "reasonText": "To provide general guidance to investigators on possible causes and management of hallucinations/psychosis.",
        "category": "Scientific",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_v7",
        "reasonText": "To accommodate participation of additional countries and account for higher-than-expected dropout rate.",
        "category": "Operational",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_v7",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "7.0",
        "beforeText": "null",
        "afterText": "Approximately 240 subjects",
        "summary": "Updated sample size estimation to 240 subjects."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_v7",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "5.1",
        "beforeText": "null",
        "afterText": "Exclude subjects positive for COVID-19",
        "summary": "Added COVID-19 exclusion criteria."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_v7",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1",
        "beforeText": "null",
        "afterText": "24 hours",
        "summary": "Changed the reporting timeframe for product complaints to 24 hours."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_v7",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "Global",
        "beforeText": "caregivers",
        "afterText": "null",
        "summary": "Removed references to caregivers throughout protocol and Operations Manual."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_v7",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.3",
        "beforeText": "null",
        "afterText": "F3 infusion rate may be reduced beyond the 20% limit from the prescribed base infusion rate (F1) if medically necessary and only with approval from the AbbVie TA MD.",
        "summary": "Clarified F3 infusion rate reduction protocols."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 4,
      "changeCount": 5
    }
  }
}